Annexin Pharmaceuticals AB (ANNX.ST)
Annexin Pharmaceuticals AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $9.02, down 3.01% on the session, giving a market capitalisation of $64.6M. Its beta of 0.31 implies it has historically moved less than the broad market.
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
Annexin Pharmaceuticals AB is most often compared with the following Healthcare names: